Literature DB >> 11959617

In vitro activity of linezolid against Clostridium difficile.

T Peláez1, R Alonso, C Pérez, L Alcalá, O Cuevas, E Bouza.   

Abstract

We examined the in vitro activity of linezolid against Clostridium difficile, including isolates with reduced susceptibility to metronidazole or vancomycin. The MIC at which 50% of the isolates were inhibited (MIC50) and MIC90 were 0.5 and 2 microg/ml, respectively (range, 0.03 to 4 microg/ml). MICs were always <or= 4 microg/ml, and thus, all isolates were considered susceptible.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11959617      PMCID： PMC127182          DOI： 10.1128/AAC.46.5.1617-1618.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Antibiotic resistance of Clostridium difficile isolates.

Authors:  A Dworczyński; B Sokół; F Meisel-Mikołajczyk
Journal:  Cytobios       Date:  1991

2.  In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

Authors:  E Cercenado; F García-Garrote; E Bouza
Journal:  J Antimicrob Chemother       Date:  2001-01       Impact factor: 5.790

3.  In vitro and in vivo activities of nitazoxanide against Clostridium difficile.

Authors:  C S McVay; R D Rolfe
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.

Authors:  J G Slatter; D J Stalker; K L Feenstra; I R Welshman; J B Bruss; J P Sams; M G Johnson; P E Sanders; M J Hauer; P E Fagerness; R P Stryd; G W Peng; E M Shobe
Journal:  Drug Metab Dispos       Date:  2001-08       Impact factor: 3.922

5.  Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia.

Authors:  M C Roghmann; R J McCarter; J Brewrink; A S Cross; J G Morris
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

6.  Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.

Authors:  S S Wong; P C Woo; W K Luk; K Y Yuen
Journal:  Diagn Microbiol Infect Dis       Date:  1999-05       Impact factor: 2.803

7.  Molecular analysis of relapse vs re-infection in HIV-positive patients suffering from recurrent Clostridium difficile associated diarrhoea.

Authors:  R Alonso; S Gros; T Peláez; D García-de-Viedma; M Rodríguez-Créixems; E Bouza
Journal:  J Hosp Infect       Date:  2001-06       Impact factor: 3.926

8.  Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents.

Authors:  D J Biedenbach; R N Jones
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

9.  In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods.

Authors:  D J Biedenbach; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2001-01       Impact factor: 2.803

10.  Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin.

Authors:  G D Rifkin; F R Fekety; J Silva
Journal:  Lancet       Date:  1977-11-26       Impact factor: 79.321
View more
  5 in total

1.  Surveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait.

Authors:  Wafaa Y Jamal; Vincent O Rotimi
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

2.  Phenotypical and Genotypical Comparison of Clostridium difficile Isolated from Clinical Samples: Homebrew DNA Fingerprinting versus Antibiotic Susceptibility Testing (AST) and Clostridial Toxin Genes.

Authors:  Javid Sisakhtpour; Fatemeh Savaheli Moghadam; Sepideh Khodaparast; Nima Khoramabadi; Ashraf Mohabati Mobarez
Journal:  Can J Infect Dis Med Microbiol       Date:  2021-12-02       Impact factor: 2.471

3.  Mobile Oxazolidinone Resistance Genes in Gram-Positive and Gram-Negative Bacteria.

Authors:  Stefan Schwarz; Wanjiang Zhang; Xiang-Dang Du; Henrike Krüger; Andrea T Feßler; Shizhen Ma; Yao Zhu; Congming Wu; Jianzhong Shen; Yang Wang
Journal:  Clin Microbiol Rev       Date:  2021-06-02       Impact factor: 50.129

4.  Antimicrobial susceptibility of clostridium difficile clinical isolates in iran.

Authors:  Mehdi Goudarzi; Hossein Goudarzi; Masoud Alebouyeh; Masoumeh Azimi Rad; Farahnaz Sadat Shayegan Mehr; Mohammad Reza Zali; Mohammad Mehdi Aslani
Journal:  Iran Red Crescent Med J       Date:  2013-08-05       Impact factor: 0.611

Review 5.  Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection.

Authors:  Simon D Baines; Mark H Wilcox
Journal:  Antibiotics (Basel)       Date:  2015-07-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.